Oxford Impedance Diagnostics Low cost, high sensitivity medical diagnostics Mr Andy Anderson Chief Executive Officer

FIRST CLASS SCIENTIFIC AND MANGEMENT TEAM Mr. Andy Anderson, Chief Executive Over 30 years senior management experience in medical diagnostics (Astra Zeneca, Becton Dickinson, Quidel) Former Chairman of the UK Diagnostics Trade Association (BIVDA, Elected 2001) MD and owner of Crawford Medical Limited since 1999 – diagnostics and SME consultancy 2013/4 Business Development Director for Alzheimer’s Diagnostic Company (P/T) Professor Jason Davis, Reader in Chemistry, University of Oxford World renowned expert with over 140 leading peer review publications Awarded in excess of £7 million of research council funding Leading academic in diagnostics, molecular & medical imaging, chemical sensing, nanotechnology, bioelectronics Professor Paulo Bueno, Research Director, Sao Paulo State University Over 130 peer reviewed publications Brazilian Ministry of Science Consultant Visiting Professor University of Oxford

CUSTOMER NEEDS MEDICAL DIAGNOSTICS Low cost tests for new/non-automatable analytes e.g. Breast Cancer Rapid test development for new biomarkers e.g. Alzheimer's Disease Highly sensitive and/or multiplex capability e.g. Insulin/CRP Laboratory or Point of Care testing capability e.g. Dengue Fever Proven health economic benefits e.g. Parkinson’s Disease

A UNIQUE PROPOSITION A platform technology with published performance data in a number of clinical applications Based upon over 5 years of high-quality, peer reviewed research in impedance technology Protected by 5 exceptionally strong patents owned by Oxford University and proprietary know-how on data handling Clinical partnerships already established driving focused test development and further research grant awards Partnership established with an experienced device developer and working prototypes already produced

THE TECHNOLOGY PLATFORM Immobilise probe to target to be measured (e.g. antibody, DNA or peptide aptamer) ASSAY DESIGN AND DEVELOPMENT 6-8 WEEKS Surface that prevents any binding of serum components SAMPLE MEASUREMENT Target capture causes change in the impedance of the electrode solution MEASURE CHANGE IN IMPEDANCE READER TIME TO RESULT 10 MINUTES

THE EXCITING PROOF OF PRINCIPLE DATA ASSAY WAS ABLE TO DIFFERENTIATE DISEASE FROM NORMAL PRE - SYMPTOMATICALLY ASSAY CORRELATES WITH LAB ELISA ASSAY Chemical Science . 2012, 3 (12) , 3468 -3473 Analytical Chem., 2013, 85, 4129-4134 EARLY STAGE PARKINSON’S DISEASE DIAGNOSTIC TEST THE MOST SENSITIVE INSULIN ASSAY EVER PRODUCED

New biomarker assay design and measurement projects PARALLEL STRATEGIES TO REDUCE RISK and GAIN EARLY REVENUE Develop and launch assays for breast cancer, dengue fever and Parkinson’s disease New biomarker assay design and measurement projects Establish platform credentials Generate high revenues/value Longer time frame Early revenues Clinical trial support Establish pharma network/collaborations

A S Y D E V L OPME N T Breast Cancer Dengue Fever Parkinson’s Disease Diagnosis via mammography and invasive biopsy Up to 30% cases missed Established companion diagnostic – HER2 (HercepTestTM) and Herceptin ANNUAL SALES POTENTIAL £300 MILLION Dengue Fever Difficult to differentiate from other viral diseases Infects 50 to 528 million people worldwide a year, leading to half a million hospitalizations 12 countries in Asia see 3 million infections and 6,000 deaths per year No commercial competitor ANNUAL SALES POTENTIAL £550 MILLION M A R K E T P O N I L Parkinson’s Disease Currently diagnosed by symptoms appearing Condition develops years before symptoms appear Therapy development hampered by lack of good biomarker >400 therapy trials underway ANNUAL SALES POTENTIAL £100 MILLION We should try to say something about Dengue if we can. Also, can we explain if asked what the likely/proposed: route to market would be Clinical care pathway – i.e. who benefits, what current provision is etc.. OUR PRODUCTS COMPANION DIAGNOSTIC HER 2 ASSAY LOW COST POINT OF CARE TEST EARLY STAGE DIAGNOSTIC TEST

SECOND STAGE INVESTMENT FOR CLINICAL TRIALS AND PRODUCT LAUNCHES THE FINANCES AND DEVELOPMENT TARGET   2015 2016 2017 2018 2019 2020 Grand Total Expenses 700,000 775,000 2,195,000 2,375,000 1,845,000 1,695,000 9,435,000 Sales 100,000 1,375,000 1,800,000 2,250,000 5,225,000 Profit -700,000 -775,000 -2,095,000 -1,000,000 -45,000 555,000 INVESTMENT OF £1.4 MILLION REQUIRED TO SET UP A COMMERCIAL DEVELOPMENT and SERVICE LABORATORY SECOND STAGE INVESTMENT FOR CLINICAL TRIALS AND PRODUCT LAUNCHES FIRST GOAL – CONVERT MANUAL SLOW ASSAY USING EXPENSIVE ELECTRODES TO SEMI-AUTOMATED CHIP SYSTEM

SUMMARY Summary Unique low risk investment opportunity in platform and assay developments High-profile assay targets with global sales potential Highly experienced business and science team Existing clinical data and working assays Leading clinical collaborators Additional development and expansion possibilities in Brazil Trade sales potential generated during development phases

CONTACT INFORMATION Andy Anderson CEO Oxford Impedance Diagnostics M: +44 (0) 7768294775 Office 01869 819886 andycrawf@zoho.com Professor Jason Davis Founder and CSO Oxford Impedance Diagnostics jason.davis@chem.ox.ac.uk